Posted on 19/11/2009 in Pharmaceutical Company Product News ALK has announced the initiation of a major study into childhood asthma.
The Grazax Asthma Prevention (GAP) trial will be the largest-ever study into the preventive effects of the condition among five to 12-year-old children who also suffer from allergic grass pollen rhinoconjunctivitis, or hay fever.
Based in Europe, the study will incorporate 600 youngsters over five years and the effectiveness of Grazax will be evaluated after three years.
The final two years will be used to monitor whether possible success of the drug is sustained after treatment.
Erkka Valorita, the lead investigator of GAP and chief paediatric allergist stated: "We will have conclusive evidence from a suitably designed trial showing that treating hay fever with the grass allergy immunotherapy tablet Grazax prevents the progression of the condition into asthma."
In September, ALK announced that Grazax had been authorised for use in 27 EU countries following the first set of results of another long-term study.
Other news stories from 19/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
